AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy
Novel Technology Reactivates the Neural Tissue after Spinal Cord Injury
May 28, 2020 10:00 AM Eastern Daylight Time
CAMBRIDGE, Mass,--(BUSINESS WIRE)--AXONIS Therapeutics, Inc., an emerging biotechnology company advancing breakthrough research to treat spinal cord injury and paralysis, today announced the close of the first tranche of a $4 million Seed Preferred financing. The financing was led by Kerry Murphy, an investor, philanthropist and AXONIS Board member. The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity. The importance of KCC2 treatment in recovery of stepping ability was first discovered by Dr. Zhigang He in his lab at Boston Children’s Hospital.
“We are very pleased with this seed funding, as it will allow us to initiate important pre-clinical work and build our team as we advance this technology,” said Joanna Stanicka, PhD, CEO, AXONIS Therapeutics. “We have seen very promising results in the proof-of-concept studies thus far, and look forward to moving this critical research to the next stage in our mission to treat paralysis.”
read...
https://www.businesswire.com/news/ho...al-Development
Novel Technology Reactivates the Neural Tissue after Spinal Cord Injury
May 28, 2020 10:00 AM Eastern Daylight Time
CAMBRIDGE, Mass,--(BUSINESS WIRE)--AXONIS Therapeutics, Inc., an emerging biotechnology company advancing breakthrough research to treat spinal cord injury and paralysis, today announced the close of the first tranche of a $4 million Seed Preferred financing. The financing was led by Kerry Murphy, an investor, philanthropist and AXONIS Board member. The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity. The importance of KCC2 treatment in recovery of stepping ability was first discovered by Dr. Zhigang He in his lab at Boston Children’s Hospital.
“We are very pleased with this seed funding, as it will allow us to initiate important pre-clinical work and build our team as we advance this technology,” said Joanna Stanicka, PhD, CEO, AXONIS Therapeutics. “We have seen very promising results in the proof-of-concept studies thus far, and look forward to moving this critical research to the next stage in our mission to treat paralysis.”
read...
https://www.businesswire.com/news/ho...al-Development
Comment